PharmaFocus Today – Page 46 – media

Implement penetrating supervision on medical institutions’ practices, drug and equipment circulation, and medical insurance fund use

Shanghai Municipal Party Committee Deputy Secretary and Mayor Gong Zheng presided over the executive meeting of the municipal government on April 14. The meeting pointed out that new forms and models of medical and health services are constantly emerging. It is necessary to improve the comprehensive supervision system of the medical and health industry, deepen comprehensive supervision with a strict tone, and shift from post-processing to full-process supervision. Relying on artificial intelligence, big data, blockchain and other technologies, implement penetrating supervision on medical institutions’ practices, drug and equipment circulation, and medical insurance fund use, and effectively protect the legitimate rights and interests of the people. It is necessary to promote innovation and development with a prudent and inclusive attitude, support and standardize the innovative development of new technologies such as medical artificial intelligence and cell therapy, as well as new forms of innovation such as Internet medical care and international ...
- Source: drugdu
- 137
- April 16, 2025
Tianyu shares wholly-owned subsidiary obtains drug registration certificate for pravastatin sodium tablets

On April 14, Tianyu shares (300702) issued an announcement that the company’s wholly-owned subsidiary Nord Pharmaceuticals recently received the “Drug Registration Certificate” for pravastatin sodium tablets approved and issued by the State Drug Administration. The drug dosage form is tablets with a specification of 40mg. It belongs to Class 4 chemical drugs. The drug approval number is National Medicine Standard H20253858, and the approval period is until April 7, 2030. It is suitable for hyperlipidemia and familial hypercholesterolemia. According to market data, the sales of pravastatin sodium tablets in domestic sample hospitals and urban physical pharmacies in 2023 are about 1.024 billion yuan. As of March 31, 2025, the company and its subsidiaries have invested approximately 9.26 million yuan in research and development on this drug. The announcement pointed out that the acquisition of the drug registration certificate will further enrich the company’s preparation varieties and specifications, and is expected ...
- Source: drugdu
- 144
- April 16, 2025
The nine-valent HPV vaccine for men is now available

After the four-valent HPV (human papillomavirus) vaccine was opened to men, on April 14, Merck China announced that Gardasil® 9 [nine-valent human papillomavirus vaccine (brewer’s yeast)] (hereinafter referred to as “nine-valent HPV vaccine”) has been approved for marketing by the National Medical Products Administration for multiple new indications and is suitable for males aged 16 to 26. This means that China has ushered in the first nine-valent HPV vaccine that can be used for male vaccination. Gardasil® 9 has become the first and currently the only approved nine-valent HPV vaccine in China that can be used for males and females of appropriate age, marking that China has officially entered a new stage of “joint prevention of HPV-related cancers and diseases for both men and women”. Although men do not develop cervical cancer, they are the main carriers of HPV virus. Globally, the male genital HPV infection rate is higher than ...
- Source: drugdu
- 324
- April 16, 2025
2025 Wuzhen Health Conference | Tasly Achieves Multiple Awards, Driving a New Future of Medicine and Health with Innovation

From April 8th to 12th, 2025, Wuzhen, a water town in Jiangnan, welcomed the annual grand event in the field of medicine and health – Wuzhen Health Conference. This industry grand event, which gathers industry elites, experts, scholars, and well-known enterprises, is an important platform for gaining insights into industry trends and exchanging innovative ideas. Tianshili Pharmaceutical Group (hereinafter referred to as “Tianshili”) won multiple awards at the conference with innovative achievements in brand strategy, product positioning, market channels, and other aspects, becoming the focus of the audience. Brand Strategy Innovation: Shaping the Influence of Innovative Traditional Chinese Medicine Drugs In terms of brand strategy, Tasly always regards innovation as the core driving force and is committed to building a Chinese medicine brand with international influence. Winning the title of “VIP Strategic Cooperation Enterprise” at the 2025 Wuzhen Health Conference is a high recognition of its brand strength and ...
- Source: drugdu
- 226
- April 15, 2025
Boya Biotechnology plans to list and transfer 80% equity of its subsidiary; Two drugs from Hengrui Pharmaceutical have been approved for clinical trials | Medical Early Reference

NO.1 Boya Biotechnology plans to publicly list and transfer 80% equity of its subsidiary On April 13th, Boya Biotechnology announced its intention to transfer 80% equity of Jiangxi Boya Xinhe Pharmaceutical Co., Ltd. (referred to as “Boya Xinhe”) through listing on the Shanghai United Property Rights Exchange, with an initial listing amount of approximately 213 million yuan. Boya Xinhe was established in 2014, and its main business is the R&D, production and sales of anti infection, diabetes, cardio cerebrovascular drugs. After the equity transfer, the company holds 10.6869% of the equity of Boya Xinhe, and its wholly-owned subsidiary Jiangxi Boya Pharmaceutical Investment Co., Ltd. holds 9.3131% of the equity of Boya Xinhe. Boya Xi nhe will no longer be included in the company’s consolidated statements. Comment: From January to December 2024, Boya Xinhe’s operating revenue was 10.1729 million yuan, total profit was -34.6187 million yuan, and net profit was ...
- Source: drugdu
- 143
- April 15, 2025
Obtained drug clinical trial approval notice

Hengrui Medicine announced on the evening of April 13 that the company received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for HRS-9190 for injection, and will conduct clinical trials in the near future. HRS-9190 for injection is a Class 1 new drug for intraoperative medication, used for tracheal intubation during the induction period of general anesthesia and maintaining skeletal muscle relaxation during surgery. The company announced on the same day that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for SHR-3792 injection, and will conduct clinical trials in the near future. SHR-3792 injection is an innovative anti-tumor drug candidate independently developed by the company, which has shown good anti-tumor activity in preclinical animal models. Upon inquiry, no similar drugs ...
- Source: drugdu
- 134
- April 15, 2025
Merck’s nine-valent HPV vaccine approved for marketing in China for male indications

On April 14, MerckAnnounced that Gardasil® 9 [9-valent human papillomavirus vaccine (crysogenyces cerevisiae)] (hereinafter referred to as “9-valent HPV vaccine”) has been approved for marketing by the National Medical Products Administration for multiple new indications, and is suitable for males aged 16 to 26. This approval makes Gardasil® 9 the first and currently the only 9-valent HPV vaccine approved in China for males and females of appropriate age. https://finance.eastmoney.com/a/202504143375989893.html
- Source: drugdu
- 148
- April 15, 2025
Servier’s “Oncology Business”

Recently, Servier spent $780 million to acquire BDTX-4933, a small molecule drug in Phase 1 clinical trials targeting RAS mutations and RAF changes in solid tumors, from Black Diamond Therapeutics. Today, Servier’s competitive position is threatened by challenges in the chronic disease drug market, and it is actively looking for a new way forward, with the latest goal of entering the field of oncology. In recent years, Servier has continuously strengthened its oncology pipeline through acquisitions and introductions, and has become a “dark horse” in the field of oncology treatment that cannot be underestimated. IDH inhibitor frontrunner Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the tricarboxylic acid cycle. There are three isoenzymes of IDHs, namely IDH1, IDH2 and IDH3. The functional loss caused by mutations in IDH1 and IDH2 will directly affect the product composition – α-ketoglutarate is converted into the carcinogenic metabolite 2-hydroxyglutarate, promoting the occurrence of ...
- Source: drugdu
- 140
- April 15, 2025
The world’s first new FcRn antagonist formulation is approved for marketing in the United States

Recently, Zai Lab’s partner argenx announced that the U.S. FDA (U.S. Food and Drug Administration) has officially approved the marketing of Efgartigimod prefilled subcutaneous injection formulation for the treatment of adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are positive for acetylcholine receptor (AChR) antibodies. Efgartigimod is the world’s first approved FcRn antagonist. Previously, its intravenous formulation (IV) and subcutaneous formulation (SC) have been approved for marketing by the FDA (U.S. Food and Drug Administration). The approval of the prefilled subcutaneous injection formulation further enriches the product form of Efgartigimod and improves the convenience of patients’ medication. This not only consolidates Argenx’s leading position in the field of FcRn antagonists, but also brings new market opportunities to Zai Lab. As Agamod continues to expand in the global market, Zai Lab is expected to share its growth dividend in the field of rare diseases through ...
- Source: drugdu
- 138
- April 15, 2025
Midea Group established the Medical Division and released Midea Medical’s annual new products

On April 8, the 91st China International Medical Equipment Fair (CMEF) opened. During the exhibition, Midea Medical held the “AI All-dimensional Intelligent Transformation 2025 Midea Medical Annual New Product Release and China Backbone Guardian Plan Launch Meeting” and officially announced the establishment of Midea Medical Division. As one of the six major business sectors of Midea Group, Midea Medical is a major breakthrough in Midea Group’s diversified development strategy. Midea Medical has the accumulation of Wandong Medical in medical diagnostic equipment and intelligent imaging solutions, Kuka Medical’s cutting-edge technology in the field of surgical robots and rehabilitation robots, Midea Biomedical’s professional advantages in medical cold chain refrigeration, Swisslog Medical’s mature solutions in hospital logistics and pharmacy automation, and Midea Building Technology’s strength in the construction and operation of smart hospitals. The synergy of these advantageous resources will further enhance Midea Medical’s industrial competitiveness. Midea Medical will also rely on Midea ...
- Source: drugdu
- 275
- April 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.